Integrating CRISPR technology with exosomes: Revolutionizing gene delivery systems.

IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Biochemical and biophysical research communications Pub Date : 2024-11-17 DOI:10.1016/j.bbrc.2024.151002
Mahintaj Dara, Mehdi Dianatpour, Negar Azarpira, Nader Tanideh, Romina Tanideh
{"title":"Integrating CRISPR technology with exosomes: Revolutionizing gene delivery systems.","authors":"Mahintaj Dara, Mehdi Dianatpour, Negar Azarpira, Nader Tanideh, Romina Tanideh","doi":"10.1016/j.bbrc.2024.151002","DOIUrl":null,"url":null,"abstract":"<p><p>CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) serves as an adaptive immune system in bacteria and archaea, offering a defense mechanism against invading genetic elements such as viruses (bacteriophages) and plasmids. Today, CRISPR has evolved into a powerful gene-editing technology that enables highly specific and rapid modifications of DNA within a genome. It has a broad range of applications across various fields, including medicine, agriculture, and fundamental research. One of the significant challenges facing this technology is the efficient transfer of CRISPR constructs into target cells for gene editing. There are several methods to deliver this system into target cells, which can be classified as viral and non-viral methods. Each of these approaches has its own advantages and disadvantages. Recently, the use of extracellular vesicles for delivery has garnered particular attention. Exosomes are nano-sized extracellular vesicles that have emerged as promising carriers for drug delivery due to their unique properties. These naturally occurring vesicles, typically ranging from 30 to 150 nm in diameter, facilitate intercellular communication by transferring bioactive molecules such as proteins, lipids, and nucleic acids between cells. Exosome therapy has surfaced as a promising strategy in regenerative medicine, utilizing small extracellular vesicles to deliver therapeutic molecules to target cells. One of the emerging options for transferring the CRISPR system is exosomes. The integration of these two advanced technologies holds significant potential for developing efficient and targeted gene editing and advancing precision medicine. In contemporary medicine, there is an increasing focus on personalized and targeted treatments that cater to the distinct genetic and molecular profiles of individual patients. The synergy of CRISPR technology and exosome therapy presents a remarkable opportunity to develop highly targeted and effective therapeutic strategies customized to individual patient requirements. This review article examines the potential of incorporating CRISPR technology within exosomes for precision therapeutic applications.</p>","PeriodicalId":8779,"journal":{"name":"Biochemical and biophysical research communications","volume":"740 ","pages":"151002"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical and biophysical research communications","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.bbrc.2024.151002","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) serves as an adaptive immune system in bacteria and archaea, offering a defense mechanism against invading genetic elements such as viruses (bacteriophages) and plasmids. Today, CRISPR has evolved into a powerful gene-editing technology that enables highly specific and rapid modifications of DNA within a genome. It has a broad range of applications across various fields, including medicine, agriculture, and fundamental research. One of the significant challenges facing this technology is the efficient transfer of CRISPR constructs into target cells for gene editing. There are several methods to deliver this system into target cells, which can be classified as viral and non-viral methods. Each of these approaches has its own advantages and disadvantages. Recently, the use of extracellular vesicles for delivery has garnered particular attention. Exosomes are nano-sized extracellular vesicles that have emerged as promising carriers for drug delivery due to their unique properties. These naturally occurring vesicles, typically ranging from 30 to 150 nm in diameter, facilitate intercellular communication by transferring bioactive molecules such as proteins, lipids, and nucleic acids between cells. Exosome therapy has surfaced as a promising strategy in regenerative medicine, utilizing small extracellular vesicles to deliver therapeutic molecules to target cells. One of the emerging options for transferring the CRISPR system is exosomes. The integration of these two advanced technologies holds significant potential for developing efficient and targeted gene editing and advancing precision medicine. In contemporary medicine, there is an increasing focus on personalized and targeted treatments that cater to the distinct genetic and molecular profiles of individual patients. The synergy of CRISPR technology and exosome therapy presents a remarkable opportunity to develop highly targeted and effective therapeutic strategies customized to individual patient requirements. This review article examines the potential of incorporating CRISPR technology within exosomes for precision therapeutic applications.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
将 CRISPR 技术与外泌体相结合:基因递送系统的革命。
CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats)是细菌和古细菌的一种适应性免疫系统,提供了一种抵御病毒(噬菌体)和质粒等遗传因子入侵的防御机制。如今,CRISPR 已经发展成为一种强大的基因编辑技术,能够对基因组内的 DNA 进行高度特异性的快速修改。它在医学、农业和基础研究等各个领域都有广泛的应用。这项技术面临的重大挑战之一是如何将 CRISPR 构建物有效地转移到目标细胞中进行基因编辑。将该系统转入靶细胞的方法有多种,可分为病毒方法和非病毒方法。这些方法各有利弊。最近,利用细胞外囊泡进行递送的方法尤其受到关注。外泌体是一种纳米大小的细胞外囊泡,由于其独特的性质,已成为很有前途的药物输送载体。这些天然存在的囊泡直径通常在 30 到 150 纳米之间,通过在细胞间传递蛋白质、脂类和核酸等生物活性分子,促进细胞间的交流。外泌体疗法是再生医学中一种前景广阔的策略,它利用小的细胞外囊泡向靶细胞输送治疗分子。外泌体是转移 CRISPR 系统的新兴选择之一。这两项先进技术的整合为开发高效、有针对性的基因编辑和推进精准医疗带来了巨大潜力。在当代医学中,人们越来越关注个性化和靶向治疗,以满足不同患者的不同基因和分子特征。CRISPR 技术和外泌体疗法的协同作用为开发高度靶向性和有效的治疗策略提供了绝佳的机会,这些策略可根据患者的个体需求进行定制。这篇综述文章探讨了将 CRISPR 技术纳入外泌体进行精准治疗应用的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Biochemical and biophysical research communications
Biochemical and biophysical research communications 生物-生化与分子生物学
CiteScore
6.10
自引率
0.00%
发文量
1400
审稿时长
14 days
期刊介绍: Biochemical and Biophysical Research Communications is the premier international journal devoted to the very rapid dissemination of timely and significant experimental results in diverse fields of biological research. The development of the "Breakthroughs and Views" section brings the minireview format to the journal, and issues often contain collections of special interest manuscripts. BBRC is published weekly (52 issues/year).Research Areas now include: Biochemistry; biophysics; cell biology; developmental biology; immunology ; molecular biology; neurobiology; plant biology and proteomics
期刊最新文献
Glutathione S-transferase: A versatile and dynamic enzyme. miRNA-124 loaded extracellular vesicles encapsulated within hydrogel matrices for combating chemotherapy-induced neurodegeneration. Syringic acid improves cyclophosphamide-induced immunosuppression in a mouse model. CEAM is a mitochondrial-localized, amyloid-like motif-containing microprotein expressed in human cardiomyocytes. Integrating CRISPR technology with exosomes: Revolutionizing gene delivery systems.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1